As an alternative interpretation, it is also possible that decreased MMP-9 levels/activity following COX-2 blockade is due to reduced activation of microglial cells and astrocytes, which would result in BBB protection after stroke (21, 23, 58–60). The gene discussed is PTGS2; the disease is stroke disorder.